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Background: Periodontal diseases are bacterial infections leading to chronic inflammation disorders that are
frequently observed in adults. In the present study, we evaluated the effect of auraptene and lacinartin, two natural
oxyprenylated coumarins, on the growth, adherence properties, and collagenase activity of Porphyromonas
gingivalis. We also investigated the capacity of these compounds to reduce cytokine and matrix metalloproteinase
(MMP) secretion by lipopolysaccharide (LPS)-stimulated macrophages and to inhibit MMP-9 activity.
Methods: Microplate dilution assays were performed to determine the effect of auraptene and lacinartin on P.
gingivalis growth as well as biofilm formation stained with crystal violet. Adhesion of FITC-labeled P. gingivalis to
oral epithelial cells was monitored by fluorometry. The effects of auraptene and lacinartin on LPS-induced cytokine
and MMP secretion by macrophages were determined by immunological assays. Fluorogenic assays were used to
evaluate the capacity of the two coumarins to inhibit the activity of P. gingivalis collagenase and MMP-9.
Results: Only lacinartin completely inhibited P. gingivalis growth in a complex culture medium. However,
under iron-limiting conditions, auraptene and lacinartin both inhibited the growth of P. gingivalis. Lacinartin
also inhibited biofilm formation by P. gingivalis and promoted biofilm desorption. Both compounds
prevented the adherence of P. gingivalis to oral epithelial cells, dose-dependently reduced the secretion of
cytokines (IL-8 and TNF-α) and MMP-8 and MMP-9 by LPS-stimulated macrophages, and inhibited MMP-9
activity. Lacinartin also inhibited P. gingivalis collagenase activity.
Conclusions: By acting on multiple targets, including pathogenic bacteria, tissue-destructive enzymes, and
the host inflammatory response, auraptene and lacinartin may be promising natural compounds for
preventing and treating periodontal diseases.
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Periodontal diseases are chronic inflammatory disorders of
bacterial origin that affect tooth-supporting tissues [1]. It is
estimated that 5% to 20% of any population suffers from se-
vere, generalized periodontitis, while mild to moderate peri-
odontitis affects a majority of adults [2]. These diseases are
mixed infections induced by a specific group of Gram-
negative anaerobic bacteria called periodontopathogens [3].
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reproduction in any medium, provided the orin the oral cavity [4] only a few are associated with peri-
odontitis, including Porphyromonas gingivalis [5]. This bac-
terial species produces a number of virulence factors that
contribute to host colonization, immune defense system
neutralization, and periodontal tissue destruction [5]. High
numbers of P. gingivalis, together with other periodonto-
pathogens, induce a host immune response, which in turn
leads to a destructive inflammatory process [6,7].
Over the past two decades, there has been increasing
interest in the potential human health benefits of natural
compounds [8]. Polyphenols, which are well known for
their antioxidant properties, contribute to the protection
of deoxyribonucleic acid (DNA) and macromoleculesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cers, cardiovascular diseases, and other disorders asso-
ciated with oxidative stress [9,10]. These natural
compounds are members of a large class of organic
molecules that are widely distributed in the plant king-
dom and, as such, are an integral part of the daily diet of
humans [11,12]. Since polyphenols have been reported
to possess antimicrobial and anti-inflammatory proper-
ties, they may be of interest as therapeutic agents for
controlling periodontal diseases, which involve both
pathogenic bacteria and host immune responses.
Auraptene and lacinartin are polyphenols that be-
long to the coumarin family [13,14]. While the chem-
ical structures of these two compounds are similar,
lacinartin has a methoxy group on the benzene ring
and an isopentenyloxy side chain (Figure 1). Aurap-
tene, which is also known as 7-geranyloxycoumarin,
was first isolated in the 1930s by Komatsu et al. [15].
It is the most abundant naturally occurring prenylox-
ycoumarin and is mostly found in Citrus fruits
[13,16,17]. Auraptene has been reported to possess
antioxidant, anti-inflammatory, antibacterial, and anti-
cancer properties [18,19] while little is known about
lacinartin.
To the best of our knowledge, no one has investi-
gated the potential beneficial effects of auraptene and
lacinartin on oral health. We hypothesized that aurap-
tene and lacinartin may be promising natural com-
pounds that could be used to prevent and treat
periodontal diseases. We thus evaluated the effects of
these compounds on the growth, biofilm formation/
desorption, and adherence to human oral epithelial
cells of P. gingivalis. We also investigated their anti-
inflammatory properties using a macrophage model as
well as their ability to inhibit MMP-9 and P. gingiva-
lis collagenase.Figure 1 Chemical structures of auraptene (A) and lacinartin
(B).Materials and methods
Compounds
Auraptene was purchased from Sigma-Aldrich Corp.
(St. Louis, MO, USA). Lacinartin, an oxyisopenteny-
lated coumarin, was produced using a previously
reported procedure [20]. Briefly, commercially avail-
able propiolic acid and pyrogallol were condensed by
concentrated H2SO4 catalysis into daphnetin via a
Pechmann reaction. The daphnetin was then select-
ively alkylated on position 7 of the coumarin ring
with 3,3-dimethylallyl bromide and 1,8-diazabicyclo
[5.4.0]undec-7-ene (DBU). It was then methylated on
position 8 with methyl iodide and triethylamine to
yield lacinartin. The final yield was 62%. Stock solu-
tions of auraptene and lacinartin were prepared in
dimethyl sulfoxide (10 mg/ml) and stored at 4°C in
the dark.
Effect on Porphyromonas gingivalis growth
P. gingivalis ATCC 33277 was purchased from the
American Type Culture Collection (Manassas, VA,
USA). Bacteria were routinely grown in Todd-Hewitt
broth (BBL Microbiology Systems, Mississauga, ON,
Canada) supplemented with 20 μM hemin and 0.0001%
vitamin K (THB-HK) at 37°C under anaerobic condi-
tions (80%N2/10%H2/10% CO2) for 24 h. The effect of
auraptene and lacinartin on P. gingivalis growth was
assessed in two different culture media using a micro-
plate dilution assay. THB-HK contained excess iron,
while Mycoplasma broth base (MBB; BBL Microbiology
Systems) supplemented with 10 μM hemin (MMB-H)
contained limited iron. Briefly, 24-h cultures of P. gingi-
valis in THB-HK, or MBB-H were diluted in fresh broth
medium to obtain an optical density of 0.2 at 660 nm
(OD660). Equal volumes (100 μl) of P. gingivalis suspen-
sion and auraptene or lacinartin (0, 12.5, 25, 50, 100 μg/
ml) in THB-HK, or MBB-H were mixed in the wells of
96-well plates (Sarstedt, Newton, NC, USA). Wells with
no P. gingivalis, auraptene, or lacinartin were used as
controls. After a 48-h incubation at 37°C under anaer-
obic conditions, bacterial growth was determined by
measuring the OD660 using a microplate reader.
Effect on P. gingivalis biofilm formation/desorption
P. gingivalis was grown in THB-HK supplemented or
not with auraptene or lacinartin as described above.
After a 48-h incubation under anaerobic conditions,
spent medium and free-floating bacteria were removed
by aspiration using a 26 G needle, and the wells were
washed three times with 50 mM phosphate-buffered sa-
line (PBS) pH 7.0. The biofilms were stained with 100 μl
of 0.02% crystal violet for 15 min. The wells were then
washed three times with PBS to remove unbound dye
and were dried for 2 h at 37°C. Ethanol (100 μl, 95%
Figure 2 Effect of auraptene (A) and lacinartin (B) on the growth of P. gingivalis in a complex medium (THB-HK) and under iron-
limiting conditions in MBB-H. Values are expressed as means ± standard deviations of triplicate assays for a minimum of three independent
experiments. Data were analyzed using the Student’s t-test (*: p≤ 0.05 vs. control without auraptene or lacinartin).
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10 min to release the dye from the biofilms. The absorb-
ance at 550 nm (A550) was measured to quantify biofilm
formation. We also investigated the capacity of auraptene
and lacinartin to promote the desorption of a P. gingivalis
biofilm. Briefly, a 48-h P. gingivalis biofilm was prepared
as described above and was treated for 2 h with auraptene
or lacinartin at final concentrations ranging from 0 to
100 μg/ml. The biofilms were stained with crystal violet as
described above. All the above assays were performed in
triplicate.
Effect on P. gingivalis adherence to oral epithelial cells
P. gingivalis cells were first labeled with fluorescein iso-
thyocyanate (FITC). Briefly, a 10-ml aliquot of a 24-h cul-
ture (THB-HK) of P. gingivalis was centrifuged at 7000 x g
for 10 min, and the pellet was suspended in 12 ml of
0.5 M NaHCO3 (pH 8) containing 0.03 mg/ml FITC. The
bacterial suspension was incubated in the dark at 37°C for30 min with constant shaking. The bacteria were then
washed three times by centrifugation (7000 x g for 5 min)
and were suspended in the original volume of PBS. The
immortalized human oral epithelial cell line GMSM-K
was kindly provided by Dr. Valerie Murrah (University of
North Carolina, Chapel Hill, NC, USA). The epithelial cells
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 4 mM L-glutamine (HyClone
Laboratories, Logan, UT, USA), 10% heat-inactivated fetal
bovine serum (FBS; Sigma Aldrich Corp.), and 100 μg/ml
of penicillin G/streptomycin at 37°C in a 5% CO2 atmos-
phere until they reached confluence. The cells were har-
vested by gentle trypsinization with 0.05% trypsin-
ethylenediaminetetraacetic acid (Invitrogen, Grand Island,
NY, USA) at 37°C and were suspended in DMEM (without
FBS). Aliquots of cell suspension (100 μl, 1.5 x 106 cells/ml)
were placed in the wells of 96-well black plates (Greiner
Bio-One, St. Louis, MO, USA). After an overnight incuba-
tion to allow the formation a confluent monolayer, spent
Figure 3 Effect of auraptene and lacinartin on P. gingivalis biofilm formation (A) and on desorption of a pre-formed P. gingivalis
biofilm (B). Values are expressed as means ± standard deviations of triplicate assays for a minimum of three independent experiments. Data were
analyzed with the Student’s t-test (*: p≤ 0.05 vs. control without auraptene or lacinartin).
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added to the wells, and the plate was incubated at room
temperature for 15 min. The formaldehyde was removed
by aspiration and the wells were washed three times with
PBS. Filtered 1% BSA (100 μl) was added to each well, andFigure 4 Effect of auraptene and lacinartin on the adherence of P. gin
means ± standard deviations of triplicate assays for a minimum of three ind
(no auraptene; no lacinartin). Data were analyzed with the Student’s t-test (the plate was incubated for 30 min at 37°C in a 5% CO2 at-
mosphere. The wells were washed once with PBS, 100 μl of
auraptene or lacinartin was added to each cell (final con-
centrations ranging from 0 to 100 μg/ml), and the plates
were incubated for 30 min. The auraptene and lacinartingivalis to human oral epithelial cells. Values are expressed as
ependent experiments. A value of 100% was assigned to the control
*: p≤ 0.05 vs. control without auraptene or lacinartin).
Figure 5 Effect of auraptene and lacinartin on the secretion of IL-8 (A) and TNF-α (B) by human macrophages stimulated with A.
actinomycetemcomitans LPS (1 μg/ml). Values are expressed as means ± standard deviations of triplicate assays for a minimum of three
independent experiments. Data were analyzed with the Student’s t-test (*: p≤ 0.05 vs. untreated control, †: p≤ 0.05 vs. control without auraptene
or lacinartin).
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shown). The FITC-labeled P. gingivalis cells were then
added (100 μl) to the wells, and the plates were incubated
in the dark for a further 90 min at 37°C under anaerobic
conditions. Unbound bacteria were removed by aspiration,
and the wells were washed three times with PBS. Relative
fluorescence units (RUF; excitation wavelength 495 nm;
emission wavelength 525 nm) corresponding to the degree
of bacterial adherence were determined using a microplate
reader. Control wells without auraptene or lacinartin were
used to determine 100% adherence values. Wells containing
only cells and auraptene or lacinartin were also prepared to
determine the autofluorescence values of the two com-
pounds. The assays were run in triplicate.
Anti-inflammatory properties in a macrophage model
U937 human monocytes (ATCC CRL-1593.2), a mono-
blastic leukemia cell line, were purchased from the
American Type Culture Collection (Manassas, VA,
USA). The cells were cultivated at 37°C in a 5% CO2atmosphere in Roswell Park Memorial Institute 1640
medium (RPMI-1640; HyClone Laboratories) supple-
mented with 10% heat-inactivated FBS and 100 μg/ml of
penicillin G/streptomycin. The monocytes (2.5 x 105
cells/ml) were then incubated in RPMI-FBS (1%) con-
taining 10 ng/ml of phorbol myristic acid (PMA; Sigma
Aldrich Corp.) for 48 h to induce differentiation into ad-
herent macrophage-like cells. Following the PMA treat-
ment, the medium was replaced with fresh medium, and
the differentiated cells were incubated for an additional
24 h prior to use. The macrophages were incubated with
auraptene or lacinartin (6.25 to 50 μg/ml) at 37°C in a
5% CO2 atmosphere for 2 h. They were then stimulated
with 1 μg/ml of Aggregatibacter actinomycetemcomitans
ATCC 29522 (serotype b) lipopolysaccharide (LPS) iso-
lated using the procedure described by Darveau and
Hancock [21]. After a 24-h incubation at 37°C in a 5%
CO2 atmosphere, the culture medium supernatants were
collected and were stored at –20°C until used. Cells
incubated in culture medium with or without auraptene
Figure 6 Effect of auraptene and lacinartin on the secretion of MMP-8 (A) and MMP-9 (B) by human macrophages stimulated with A.
actinomycetemcomitans LPS (1 μg/ml). Values are expressed as means ± standard deviations of triplicate assays for a minimum of three
independent experiments. Data were analyzed with the Student’s t-test (*: p≤ 0.05 vs. untreated control).
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controls. Commercial enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems, Minneapolis, MN,
USA) were used to quantify IL-8, TNF-α, MMP-8, and
MMP-9 concentrations in the cell-free culture superna-
tants according to the manufacturer’s protocols. The ab-
sorbance at 450 nm was read using a microplate reader
with the wavelength correction set at 550 nm.
Inhibition of MMP-9 and P. gingivalis collagenase activity
Human recombinant MMP-9 (active form) purchased
from Calbiochem (San Diego, CA, USA) was diluted in re-
action buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM
CaCl2, and 0.02% Brij 35) to a concentration of 1 μg/ml
and was incubated for 18 h in the absence or presence of
auraptene or lacinartin (0-100 μg/ml) and fluorogenic sub-
strate (100 μg/ml). To determine the effect of auraptene
and lacinartin on P. gingivalis collagenase activity, a 48-h
THB-HK culture was centrifuged at 10 000 x g for 10 min.
The supernatant was then incubated for 18 h in the ab-
sence or presence of auraptene or lacinartin (0-100 μg/ml)
and fluorogenic substrate (100 μg/ml). Gelatin DQTM and
collagen DQTM (Molecular Probes, Eugene, OR, USA)were used to quantify MMP-9 and P. gingivalis collage-
nase activities, respectively. The assay mixtures were incu-
bated for 18 h at 37°C for MMP-9 and at room
temperature for P. gingivalis collagenase. The fluorescence
was measured after 4 h using a microplate reader with the
excitation and emission wavelengths set at 495 nm and
525 nm, respectively. Fluorescent substrates alone or with
auraptene and lacinartin were used as controls. Specific
inhibitors of MMP-9 (0.025 μM GM6001) and P. gingiva-
lis collagenase (1 μM leupeptin) were tested. The assays
were run in triplicate.
Statistical analysis
Results are expressed as the means ± standard deviations
of three independent experiments. The data were ana-
lyzed using the Student’s t-test. A p value ≤ 0.05 was
considered statistically significant.
Results
Lacinartin (50 and 100 μg/ml) almost completely inhib-
ited the growth of P. gingivalis in THB-HK (Figure. 2B),
while the highest concentration of auraptene tested
(100 μg/ml) only reduced growth by 42% (Figure. 2A).
Table 1 Effect of auraptene and lacinartin on the activity





None 100± 1 100 ± 3
Commercial inhibitor1 56 ± 1 6 ± 5
Auraptene 100 μg/ml 27 ± 1 110 ± 4
50 27 ± 1 113 ± 5
25 27 ± 3 113 ± 1
12.5 26 ± 1 107 ± 10
Lacinartin 100 μg/ml 19 ± 6 36± 3
50 25 ± 1 49± 1
25 31 ± 2 69± 1
12.5 26 ± 3 80 ±1
1Inhibitor of MMP-9: GM6001 (0.025 μM); inhibitor of P. gingivalis collagenase:
leupeptin (1 μM).
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0.59), which represents an iron poor condition for P.
gingivalis, than in THB-HK (OD660 = 0.78) (Figure. 2).
The lowest concentration of auraptene tested (12.5 μg/
ml) inhibited growth by 58% in MBB-H, while such a
concentration had no significant inhibitory effect in
THB-HK (Figure. 2A). Almost complete inhibition was
observed at higher concentrations (50 and 100 μg/ml).
As for auraptene, lacinartin seemed to be more effective
for inhibiting growth of P. gingivalis in iron-limiting
conditions.
Auraptene had no obvious inhibitory effect on P. gingi-
valis biofilm formation or desorption (Figure. 3). On the
contrary, high concentrations (50 and 100 μg/ml) of aur-
aptene appear to increase biofilm formation
(Figure. 3A). Lacinartin at 50 and 100 μg/ml inhibited
biofilm formation by P. gingivalis by approximately 75%
(Figure. 3A). In addition, lacinartin (12.5-100 μg/ml)
caused approximately one-third of the biofilm to desorb
(Figure. 3B).
Auraptene and lacinartin both dose-dependently
inhibited bacterial adhesion to oral epithelial cells (Fig-
ure. 4). At the lowest concentration tested (12.5 μg/ml),
auraptene and lacinartin reduced the adherence of P.
gingivalis to epithelial cells by 33% and 43%, respectively,
while 100 μg/ml of auraptene and lacinartin reduced ad-
herence by 37% and 71%, respectively (Figure. 4).
The highest non-cytotoxic concentrations of auraptene
and lacinartin that can be used to evaluate their effect on
the inflammatory response of a human macrophage model
stimulated with LPS were 25 and 50 μg/ml, respectively
(data not shown). Following a 2-h pretreatment of the
model with auraptene (6.25, 12.5, and 25 μg/ml) or lacinar-
tin (12.5, 25, and 50 μg/ml), macrophages were stimulated
with LPS to induce an inflammatory response (cytokine
and MMP secretion). Auraptene and lacinartin both had asignificant inhibitory effect on IL-8 and TNF-α secretion.
At the lowest concentration tested (6.25 μg/ml), auraptene
reduced IL-8 and TNF-α secretion by 22% and 37%, re-
spectively, compared to untreated cells, while at the highest
concentration tested (25 μg/ml), it inhibited IL-8 and TNF-
α secretion by 92% and 85%, respectively (Figure. 5). As
shown in Fig. 5, the highest concentration of lacinartin
tested (50 μg/ml) reduced IL-8 and TNF-α secretion by
95% and 99%, respectively, while 12.5 and 25 μg/ml of laci-
nartin increased the secretion of both cytokines, likely due
to a synergistic effect of LPS and lacinartin, since lacinartin
alone had no effect (data not shown). Auraptene and laci-
nartin both reduced MMP-8 and MMP-9 secretion, some-
times below basal levels (Figure. 6). Auraptene reduced
MMP-8 secretion by 63% (6.25 μg/ml), 69% (12.5 μg/ml),
and 73% (25 μg/ml), while lacinartin reduced MMP-8 se-
cretion by 79% (12.5 μg/ml), 83% (25 μg/ml), and 89%
(50 μg/ml) (Figure. 6A). At their highest concentrations
tested, auraptene (25 μg/ml) reduced MMP-9 secretion by
76% (25 μg/ml) (Figure. 6B), while lacinartin (50 μg/ml)
reduced MMP-9 secretion by 82% (Figure. 6B).
After demonstrating that auraptene and lacinartin can
decrease MMP secretion in a macrophage model, we
evaluated their effect on proteinase activity. Both aurap-
tene and lacinartin (12.5 μg/ml) reduced MMP-9 activity
by 74% (Table 1). Auraptene had no inhibitory effect on
P. gingivalis collagenase activity while 12.5 μg/ml and
100 μg/ml of lacinartin reduced collagenase activity by
20% and 64%, respectively (Table 1).
Discussion
Periodontal diseases are polymicrobial infections and are
the most common chronic inflammatory disorders in
adults [22]. Periodontitis is induced by a specific group
of Gram-negative anaerobic bacteria and is the major
cause of tooth loss in adults [23]. Over the past two dec-
ades, natural compounds with antibacterial and anti-
inflammatory properties have received considerable
attention as new therapeutic agents for the treatment of
periodontal infections. In this study, we investigated the
potential of auraptene and lacinartin for preventing and
treating periodontal diseases.
We first showed that lacinartin and to a lesser extent
auraptene reduced P. gingivalis growth. This is the first
report indicating that lacinartin possesses anti-bacterial
properties. Previous studies have shown that auraptene
has antibacterial properties against Helicobacter pylori
[24,25]. The exact mechanism by which lacinartin and
auraptene inhibit bacterial growth is unknown. However,
other natural coumarins (novobiocin and clorobiocin)
inhibit deoxyribonuclease gyrase activity, which results
in bacteria death [14,26]. In addition, we showed that
auraptene and lacinartin inhibit growth more effectively
under iron-limiting conditions, requiring much lower
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gingivalis. Our results are in agreement with those of
Mladnka et al. [27], who showed that coumarins possess
iron-chelating properties. Additional studies are required
to investigate interactions between iron and auraptene
and lacinartin.
We also showed that lacinartin, but not auraptene,
inhibits biofilm formation by P. gingivalis. Lacinartin
also caused the desorption of a pre-formed P. gingiva-
lis biofilm. To the best of our knowledge, this is the
first report regarding the inhibitory effects of lacinar-
tin on bacterial biofilms. Auraptene and lacinartin
prevented the adherence of P. gingivalis to oral epi-
thelial cells to a significant degree. Epithelial cells act
as a physical barrier, and bacterial adherence to these
host cells may be a critical step for the initiation of
periodontal diseases [28]. Given its ability to reduce
growth of P. gingivalis and its adherence to epithelial
cells, lacinartin may be a promising therapeutic candi-
date through its action on different targets.
Polyphenols reduce inflammatory mediator secretion
and, as such, inflammation-mediated damage [29]. We
showed that auraptene markedly reduces IL-8 and TNF-
α secretion by LPS-stimulated macrophages. Our results
are in agreement with those of Genovese et al., who
reported that auraptene inhibits the release of TNF-α by
RAW 264.7 macrophages [30]. To our knowledge, no
one has investigated the anti-inflammatory properties of
lacinartin. We showed that 12.5 μg/ml of lacinartin
induced IL-8 and TNF-α secretion, likely due to a syner-
gistic interaction between LPS and lacinartin. On the
other hand, 50 μg/ml of lacinartin significantly inhibited
IL-8 and TNF-α secretion. We also showed that aurap-
tene and lacinartin reduced MMP-8 and MMP-9
secretion. These results are in agreement with those of a
study by Epifano et al., who reported that auraptene
inhibits MMP-7 secretion by HT-29 epithelial cells [18].
Since MMP release and cytokine secretion are associated
with tooth-supporting tissue destruction, our results
suggested that both compounds may contribute to redu-
cing host cell damage, including bone resorption [5,31].
The mechanisms by which auraptene and lacinartin re-
duce inflammatory mediator secretion are unknown, but
previous studies have shown that coumarins can block
the activation of nuclear factor-κB and inhibit kinase
pathways (Akt/PKB) [26]. Considering that gingival
fibroblasts may also play a significant role in periodontal
tissue destruction through cytokine-inducible MMP se-
cretion, future studies should investigate the effects of
auraptene and lacinartin on this cell type.
We further showed that auraptene and lacinartin re-
duce MMP-9 activity while only lacinartin inhibits P.
gingivalis collagenase activity. Auraptene has previously
been shown to inhibit MMP-7 activity [32]. Theseobservations suggest that these coumarins may contrib-
ute to reducing tissue destruction.Conclusions
In conclusion, our study provided new information on
auraptene and lacinartin indicating that they possess an
array of interesting antimicrobial, anti-adhesion, anti-
inflammatory and anti-protease properties that may be
useful for the prevention and treatment of periodontal
diseases. Since auraptene and lacinartin act on both
etiologic factors of periodontal diseases (periodonto-
pathogens and the host inflammatory response), they
may be an alternative to traditional antimicrobials. Fur-
ther studies are required to investigate the mechanisms
of these coumarins, especially the mechanisms involved
in their anti-inflammatory activity.
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